BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 8050491)

  • 1. Are LIF and related cytokines functionally equivalent?
    Piquet-Pellorce C; Grey L; Mereau A; Heath JK
    Exp Cell Res; 1994 Aug; 213(2):340-7. PubMed ID: 8050491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of SSEA-1- and Oct-4-expressing rat embryonic stem-like cell lines and effects of cytokines of the IL-6 family on clonal growth.
    Vassilieva S; Guan K; Pich U; Wobus AM
    Exp Cell Res; 2000 Aug; 258(2):361-73. PubMed ID: 10896787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells.
    Liu J; Hadjokas N; Mosley B; Estrov Z; Spence MJ; Vestal RE
    Cytokine; 1998 Apr; 10(4):295-302. PubMed ID: 9617575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemia inhibitory factor and neurotrophins support overlapping populations of rat nodose sensory neurons in culture.
    Thaler CD; Suhr L; Ip N; Katz DM
    Dev Biol; 1994 Feb; 161(2):338-44. PubMed ID: 8313987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncostatin M is a differentiation factor for myeloid leukemia cells.
    Bruce AG; Hoggatt IH; Rose TM
    J Immunol; 1992 Aug; 149(4):1271-5. PubMed ID: 1380037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncostatin M (OSM) stimulates resorption and inhibits synthesis of proteoglycan in porcine articular cartilage explants.
    Hui W; Bell M; Carroll G
    Cytokine; 1996 Jun; 8(6):495-500. PubMed ID: 8818547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formation of autocrine loops in human cerebral meningioma tissue by leukemia inhibitor factor, interleukin-6, and oncostatin M: inhibition of meningioma cell growth in vitro by recombinant oncostatin M.
    Schrell UM; Koch HU; Marschalek R; Schrauzer T; Anders M; Adams E; Fahlbusch R
    J Neurosurg; 1998 Mar; 88(3):541-8. PubMed ID: 9488310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokines involving gp130 in signal transduction suppressed growth of a mouse hybridoma cell line and enhanced its antibody production.
    Terada S; Suzuki E; Ueda H; Makishima F
    Cytokine; 1996 Dec; 8(12):889-94. PubMed ID: 9050746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A ciliary neurotrophic factor-sensitive human myeloma cell line.
    Gu ZJ; Zhang XG; Hallet MM; Lu ZY; Wijdenes J; Rossi JF; Klein B
    Exp Hematol; 1996 Aug; 24(10):1195-200. PubMed ID: 8765494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma.
    Wierzbowska A; Urbańska-Ryś H; Robak T
    Br J Haematol; 1999 May; 105(2):412-9. PubMed ID: 10233412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncostatin M binds the high-affinity leukemia inhibitory factor receptor.
    Gearing DP; Bruce AG
    New Biol; 1992 Jan; 4(1):61-5. PubMed ID: 1536831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GP130/OSMR is the only LIF/IL-6 family receptor complex to promote osteoblast differentiation of calvaria progenitors.
    Malaval L; Liu F; Vernallis AB; Aubin JE
    J Cell Physiol; 2005 Aug; 204(2):585-93. PubMed ID: 15751050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells.
    Klausen P; Pedersen L; Jurlander J; Baumann H
    Oncogene; 2000 Jul; 19(32):3675-83. PubMed ID: 10951574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of cartilage proteoglycan metabolism by LIF binding protein.
    Hui W; Bell MC; Carroll GJ; Layton MJ
    Cytokine; 1998 Mar; 10(3):220-6. PubMed ID: 9576068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family.
    Montero-Julian FA; Brailly H; Sautès C; Joyeux I; Dorval T; Mosseri V; Yasukawa K; Wijdenes J; Adler A; Gorin I; Fridman WH; Tartour E
    Clin Cancer Res; 1997 Aug; 3(8):1443-51. PubMed ID: 9815830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning and biological activity of murine oncostatin M.
    Hara T; Ichihara M; Yoshimura A; Miyajima A
    Leukemia; 1997 Apr; 11 Suppl 3():449-50. PubMed ID: 9209421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand/receptor signaling threshold (LIST) model accounts for gp130-mediated embryonic stem cell self-renewal responses to LIF and HIL-6.
    Viswanathan S; Benatar T; Rose-John S; Lauffenburger DA; Zandstra PW
    Stem Cells; 2002; 20(2):119-38. PubMed ID: 11897869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paracrine induction of stem cell renewal by LIF-deficient cells: a new ES cell regulatory pathway.
    Dani C; Chambers I; Johnstone S; Robertson M; Ebrahimi B; Saito M; Taga T; Li M; Burdon T; Nichols J; Smith A
    Dev Biol; 1998 Nov; 203(1):149-62. PubMed ID: 9806780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
    Westendorf JJ; Jelinek DF
    J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene.
    Liu J; Spence MJ; Wallace PM; Forcier K; Hellström I; Vestal RE
    Cell Growth Differ; 1997 Jun; 8(6):667-76. PubMed ID: 9186000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.